Hill Stephen J. 4

What Happened
Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma (LYEL), reported a sale of 1,236 shares on 2026-02-11. The weighted-average sale price was $23.39 per share, resulting in proceeds of approximately $28,910. This was a sale (S) and not a purchase—specifically, the shares were sold to satisfy tax-withholding obligations tied to the settlement of performance-based vested restricted stock units.

Key Details

• Transaction date: 2026-02-11; Form 4 filed 2026-02-12 (appears timely).
• Transaction type: Sale (S); 1,236 shares disposed.
• Price: weighted average $23.39; reported range $23.3939–$24.7850 per share (issuer/SEC can request breakdown by price).
• Proceeds: ~ $28,910.
• Reason/footnote: F1 — shares automatically sold to cover tax withholding from settlement of performance-based vested RSUs. F2 — weighted-average price reported; range provided.
• Shares owned after transaction: not provided in the excerpt; see the Form 4 filing for post-transaction holdings.

Context
Sales to cover tax-withholding on vested RSUs are common and reflect a routine administrative step rather than an explicit view on the company. The filing includes a price range and notes the issuer or SEC staff can request the exact breakdown of shares sold at each price.